Combining chemotherapy with CAR-T cell therapy in treating solid tumors

Frontiers in Immunology

Immunology

Xiao Jing Ong¹  Arthur Xuan Wang¹  Paul J. Neeson²  Criselle D’Souza²  Joe Jiang Zhu² 

[1] Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, VIC, Australia;

关键词: chemotherapy;    Chimeric Antigen Receptor T cell (CAR-T);    solid tumor;    tumor microenvironment (TME);    personalized combination;   

DOI  :  10.3389/fimmu.2023.1140541

 received in 2023-01-09, accepted in 2023-02-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

Chemotherapy has long been a standard treatment for a wide range of malignancies, where patients typically undergo multiple rounds of chemotherapy regimens to control tumor growth. In the clinic, the chemotherapy drugs cyclophosphamide and fludarabine are commonly used prior to Chimeric Antigen Receptor T (CAR-T) cell therapy to lymphodeplete and improve CAR-T cell engraftment. In this review, we discuss the use of chemotherapy in combination with CAR-T cell therapy. We also show that chemotherapy can deplete immunosuppressive cells, promote a pro-inflammatory tumor microenvironment, disrupt tumor stroma, and improve CAR-T cell recruitment to the tumor. Although the combination of chemotherapy plus CAR-T cell therapy is promising, certain aspects of chemotherapy also pose a challenge. In addition, the combined therapeutic effect may be heavily dependent on the dose and the treatment schedule. Thus, we also discussed the obstacles to effective clinical outcomes of the combination therapy.

【 授权许可】

Unknown   
Copyright © 2023 Wang, Ong, D’Souza, Neeson and Zhu